Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression

This invention identifies a previously uncharacterized factor in pancreatic malignancy, ZIP4, and thereby identifies a target for cancer therapy. Agents that inhibit ZIP4 provide methods and compositions to treat cancer, specifically, pancreatic cancer.